Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis
复制标题
DOI：
10.1016/j.jneuroim.2012.07.003
复制
发表时间：
2012-10-15
影响因子：
3.3
通讯作者：
Miller, Ariel
中科院分区：
文献类型：
--
作者：
Toubi, Elias;Nussbaum, Shahar;Miller, Ariel
Laquinimod is an orally administered drug under development for the treatment of Multiple Sclerosis (MS), lacking a fully elucidated mode of action. We assessed the immunomodulatory effects of laquinimod in vitro on human B cells from healthy or MS patients, cultured alone or with CD4(+) T cells. Laquinimod modulated B cell markers, mainly by increasing the regulatory ones CD25, Il10 and CD86, and decreased IL4, while increasing MO and TGF beta in both B and T cells, in a B cell-mediated manner. These findings shed additional light on the mechanisms underlying the effects of laquinimod in MS and potentially other immune-mediated diseases. (C) 2012 Elsevier B.V. All rights reserved.
